These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27230034)

  • 1. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.
    Benslama N; Bollard J; Vercherat C; Massoma P; Roche C; Hervieu V; Peron J; Lombard-Bohas C; Scoazec JY; Walter T
    Invest New Drugs; 2016 Oct; 34(5):654-62. PubMed ID: 27230034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
    Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
    Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J; Kulke M
    Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
    Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
    Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
    Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
    Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
    Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
    Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
    Rose DB; Nellesen D; Neary MP; Cai B
    J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
    Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
    Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.
    de Lima M; Hajj G; de Lima V; Alves FA
    Oral Dis; 2018 Mar; 24(1-2):207-209. PubMed ID: 29480592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial.
    Pavel ME; Becerra C; Grosch K; Cheung W; Hasskarl J; Yao JC
    Clin Pharmacol Ther; 2017 Apr; 101(4):462-468. PubMed ID: 28032910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
    Bainbridge HE; Larbi E; Middleton G
    Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.